These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 36582799)

  • 1. Targeted therapy of RET fusion-positive non-small cell lung cancer.
    Shen Z; Qiu B; Li L; Yang B; Li G
    Front Oncol; 2022; 12():1033484. PubMed ID: 36582799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
    Nguyen VQ; Geirnaert M
    J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.
    Takamori S; Matsubara T; Haratake N; Toyokawa G; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Taguchi K; Okamoto T; Seto T
    Front Oncol; 2021; 11():704084. PubMed ID: 34497761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
    Sun F; McCoach CE
    Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RET Inhibitors in Non-Small-Cell Lung Cancer.
    Cascetta P; Sforza V; Manzo A; Carillio G; Palumbo G; Esposito G; Montanino A; Costanzo R; Sandomenico C; De Cecio R; Piccirillo MC; La Manna C; Totaro G; Muto P; Picone C; Bianco R; Normanno N; Morabito A
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.
    Ke JY; Huang S; Jing ZT; Duan MC
    Invest New Drugs; 2023 Oct; 41(5):768-776. PubMed ID: 37603207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Syed YY
    Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pralsetinib for the treatment of a
    Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
    Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
    Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
    Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
    Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
    Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring
    Qin H; Wan Y; Dong Y; Sun Q
    Cancer Manag Res; 2023; 15():765-769. PubMed ID: 37525669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.
    De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A
    Front Oncol; 2024; 14():1307458. PubMed ID: 38420011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
    Spitaleri G; Trillo Aliaga P; Attili I; Del Signore E; Corvaja C; Pellizzari G; Katrini J; Passaro A; de Marinis F
    Cancers (Basel); 2024 Aug; 16(16):. PubMed ID: 39199650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
    Nguyen L; Monestime S
    Am J Health Syst Pharm; 2022 Mar; 79(7):527-533. PubMed ID: 34864862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer.
    Wan R; Li W; Wang Z; Zhong J; Lin L; Duan J; Wang J
    Heliyon; 2024 Jan; 10(2):e24796. PubMed ID: 38304763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.